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HEALTH AND MEDICINE

Identification of kidney injury–released circulating
osteopontin as causal agent of respiratory failure
Fatima Zohra Khamissi†, Liang Ning†, Eirini Kefaloyianni, Hao Dun, Akshayakeerthi Arthanarisami,
Amy Keller, Jeffrey J. Atkinson, Wenjun Li, Brian Wong, Sabine Dietmann, Kory Lavine,
Daniel Kreisel, Andreas Herrlich*
Tissue injury can drive secondary organ injury; however, mechanisms and mediators are not well understood. To
identify interorgan cross-talk mediators, we used acute kidney injury (AKI)–induced acute lung injury (ALI) as a
clinically important example. Using kidney and lung single-cell RNA sequencing after AKI in mice followed by
ligand-receptor pairing analysis across organs, kidney ligands to lung receptors, we identify kidney-released
circulating osteopontin (OPN) as a novel AKI-ALI mediator. OPN release from kidney tubule cells triggered lung
endothelial leakage, inflammation, and respiratory failure. Pharmacological or genetic OPN inhibition
prevented AKI-ALI. Transplantation of ischemic wt kidneys caused AKI-ALI, but not of ischemic OPN–global knockout kidneys, identifying kidney-released OPN as necessary interorgan signal to cause AKI-ALI. We show that OPN
serum levels are elevated in patients with AKI and correlate with kidney injury. Our results demonstrate
feasibility of using ligand-receptor analysis across organs to identify interorgan cross-talk mediators and may
have important therapeutic implications in human AKI-ALI and multiorgan failure.

Washington University School in St. Louis School of Medicine, 660 S Euclid Avenue,
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expression in the kidney, and elevated serum levels of IL6 and TNF
protein after AKI were generally interpreted to result from release
of these mediators by the injured kidney. However, AKI-ALI mediator expression has also been reported in extrarenal organs, such as
IL6 expression in the liver, spleen, or lung (15, 16), but cell type–
specific KOs (kidney or other) of reported AKI-ALI mediators have
not been tested in AKI-ALI models. Thus, it has not been conclusively shown that only or mainly the kidney serves as a source of
these mediators after kidney injury. Furthermore, which lung cell
types or immune cells are targeted by these mediators is largely unknown, except for a possible role of the TNF receptor TNFR1 in
apoptosis of lung endothelial cells during AKI-ALI (17). Tissue-
specific immune cell responses, in particular, of tissue resident or
recruited macrophages, in the lung, heart, brain, liver, or kidney in
response to myocardial infarction, stroke, or sepsis have been described (18). These immune cells might represent mediator targets,
but interorgan signals that drive these responses or target immune
cells are still largely unknown.
Hormones, growth factors, chemokines, cytokines, neurotransmitters, and other secreted proteins (in the following referred to as
ligands) act in cell-cell communication in an autocrine/paracrine
fashion locally but may have distant endocrine effects if released
into the circulation. These ligands could be relevant for interorgan
cross-talk, such as in the case of IL6 and TNF. We therefore chose
to concentrate first on soluble ligands expressed in the kidney with
the idea that these and the responding receptors expressed in lung
cells will lead us to identify relevant causal mediators of interorgan
communication. Ligand-induced cognate receptor activation in receiving cells generally results in altered gene expression and phenotypic changes. To date, ligand-receptor (L-R) pairing analysis using
bulk or single-cell or single-nucleus RNA sequencing (scRNAseq or
snRNA-seq) gene expression datasets has been used to infer cell-cell
communication within a local tissue or organ (1, 4). Here, we present, to our knowledge, the first L-R pairing analysis across different
organs to successfully determine a mediator of interorgan cross-talk
in multiorgan failure in vivo. Our studies identify kidney tubule
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INTRODUCTION

Homeostasis in multicellular organisms and the response to its disturbance by injury is coordinated by cell-cell communication aimed
at maintaining and reestablishing homeostasis (1–3). Studies on
cellular functions in health and disease to date mostly focus on understanding cell-cell communication and its mediators within a given
organ or diseased tissue (4). However, mediators of interorgan cross-
talk between cells in different organs or tissues that drive multi
organ failure in complex diseases with high mortality and their
cellular sources and target cells are largely unknown. Clinically important examples of this interorgan cross-talk include acute kidney
injury (AKI)–induced acute lung injury (ALI) with respiratory failure (5, 6), ALI, or its most severe form—acute respiratory distress
syndrome (ARDS)—followed by AKI (7, 8), or lung transplant–
induced AKI (9).
We investigated interorgan cross-talk using the example AKIALI. AKI is a common problem in the human population and develops in 2 to 5% of patients during hospitalization, in 50% of
intensive care unit patients, and in about 20% of kidney transplant
patients within the first 6 months after transplantation (9). Irrespective of its cause, AKI alone has a 15 to 30% mortality, which rises to
60 to 80% when AKI induces remote secondary organ complications
(multiorgan failure), particularly AKI-ALI (5, 6, 10). Molecular
mechanisms and mediators of AKI-ALI are not yet well understood
[reviewed in (5, 6, 11, 12)]. Candidate AKI-ALI mediators were
largely derived from global gene knockout (KO) studies or from the
use of systemic interventions. These studies implicated interleukin-6
(IL6) (13, 14) and tumor necrosis factor (TNF) (15), as well as IL10
released from splenic CD4 T cells (16), the alarmin high mobility
group box-1 (13), and CD8+ T cells (14) as putative mediators. For
IL6 or TNF, as examples, it is known that AKI up-regulates their
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cell–released circulating osteopontin (OPN) as a key causal mediator of AKI-induced remote ALI with respiratory failure (AKI-ALI).
RESULTS

scRNAseq of kidney and lung in setting of AKI-ALI
As an entrance into identifying relevant cellular changes after AKI,
we analyzed cellular gene expression profiles by scRNAseq of kidneys and lungs isolated on day 1 after sham operation or bilateral
renal IRI-induced AKI (Fig. 2A, experimental scheme). Serum BUN
levels were significantly elevated in injured mice on day 1 after AKI
(Fig. 2B), indicating severe AKI. Analysis of scRNAseq gene expression
profiles revealed the presence of all known nonimmune and immune
cell types of the kidney and lung. Seurat objects that combine the
Khamissi et al., Sci. Adv. 8, eabm5900 (2022)
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L-R pairing analysis across organs, linking ligands expressed
in the kidney to receptors expressed in the lung
To infer possible cell-cell communication events between kidneys
and lungs, we used the machine learning algorithm CellPhoneDB
(21) to perform computational L-R pairing analysis across organs,
with ligands located in the kidney and their cognate receptors in the
lung (Fig. 3A). The CellPhoneDB L-R interaction database used here
is unique in that, beyond classical ligand and receptor interactions,
it also considers other interaction partners that may participate in
signaling, such as co-receptors or other receptor-associated proteins.
We considered only L-R interactions with the ligand expressed in a
kidney cell type and its cognate receptor expressed in a lung cell type.
Notably, CellPhoneDB calculates an empirical P value, with higher
P values indicating higher predicted significance of the L-R pairing.
We divided our analysis into L-R pairings from nonimmune
cells or immune cell types in the kidney to nonimmune cells or immune cell types in the lung, either at baseline (sham) or after injury
(AKI kidney or AKI-ALI lung). The top scoring L-R pairing detected
at baseline and after injury was tubule cell-expressed OPN [or secreted phosphoprotein-1 (SPP1)] pairing with its receptor CD44 in
lung nonimmune and immune cell types. The significance of these
predicted interactions was P > 2.5 at baseline, which significantly
increased to P > 4.5 after injury. At baseline, distal tubule cells represented the main source of OPN, but, by day 1 after AKI, proximal
tubule cells were also predicted to significantly participate in OPN:
CD44 signaling (Fig. 3, B and C, panels 1 and 2). CD44 has several
other ligands, some of which were also detected in the L-R pairing
analysis, such as hepatocyte growth factor (HGF):CD44 or fibroblast growth factor 2 (FGF2):CD44, but these pairings were limited
to kidney immune to lung immune cell pairings and of low to moderate significance that did not change with injury (fig. S1A, panels 1
and 2). For kidney immune cells, the top scoring L-R pairings, however, with low difference in significance between sham and injured
samples (P >2.5 ➔ 3) included (i) kidney neutrophil IL1 connecting
to 2-adrenergic receptor (IL1b:Adrb2) in lung immune or stromal
cells and (ii) kidney T cell chemokine ligand 5 (CCL5) connecting
to CCR1-5/atypical chemokine receptor 4 (Ackr4) receptors in lung
immune or nonimmune cells (fig. S1, A and B, panels 1 and 2). The
significance of the IL1b:Adrb2 pairing is unclear, as this pairing is
predicted by CellPhoneDB on the basis of protein-protein interaction data curated from various experimental approaches (22, 23), but
it is not known whether this interaction produces a cellular signal.
2 of 19
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Ischemic AKI causes severe ALI
Aiming at identifying communication between an injured tissue
and other organs, we established a model of multiorgan failure. We
chose to injure the kidney and study remote effects on the lung. We
subjected C57BL/6 mice to bilateral renal ischemia-reperfusion
injury (IRI) and analyzed remote ALI (AKI-ALI) (Fig. 1A, experimental scheme). Kidney injury caused highly elevated blood urea
nitrogen (BUN) levels on day 1 after AKI, indicating severe kidney
failure, with slow improvement by about 50% over days 3 to 5 (Fig. 1B).
Consistent with this, serum creatinine was significantly elevated on
day 1 and remained elevated at lower levels over days 3 to 5 (Fig. 1C).
Severe injury to lungs and inflammation (AKI-ALI) followed with
the same kinetics, as determined by expansion of interstitial spaces,
increased cellularity and interstitial edema (Fig. 1D). Alveolar wall
thickness increased over sham levels by 75% on day 1, signaling impediment of oxygenation (Fig. 1E). Neutrophils and interstitial
macrophages (IMs) accumulated in the lung, peaked on day 1 after
AKI, and were still significantly elevated by day 5. IMs that accumulated in lungs after AKI are small and CD68low. Alveolar macrophages
(CD68high) did not change in numbers (Fig. 1F). We confirmed these
results by mass cytometry [cytometry by time of flight (CyTOF)] of
lung single-cell preparations from sham and AKI mice (Fig. 1G).
Analysis of lung bronchoalveolar lavage (BAL) fluid on day 1 after
AKI as compared to BAL fluid from sham controls showed significantly increased total protein and albumin concentration (Fig. 1H),
as well as increased total immune cells and neutrophils; alveolar
macrophage numbers were similar to sham control (Fig. 1I). These
BAL findings are consistent with substantial AKI-ALI. The functional consequence of these changes was a significant impairment
in oxygen exchange on day 1 after AKI (Fig. 1J). Our mouse data
thus closely resemble what can be observed in patients with multiorgan failure after AKI (5, 6, 8).
To exclude that the observed AKI-ALI phenotype is simply the
result of accumulation of toxic waste products or failure to excrete
an existing potentially detrimental molecule because of lack of
glomerular filtration, we examined mice for AKI-ALI on day 1 after
simple bilateral nephrectomy, without reperfusion injury. Sham-
operated mice or animals that underwent bilateral nephrectomies
showed no differences in terms of lung interstitial spaces and cellularity (Fig. 1K), alveolar wall thickness (Fig. 1L), or lung immune
cell numbers as assessed by CyTOF on day 1 after nephrectomy
(Fig. 1M). These findings indicate that AKI-ALI in our model does
not develop simply because of a failure to excrete a potentially detrimental molecule.

data for sham and injury, as well as dotplots identifying standard
marker genes used to identify cell types (19, 20), for either kidney
(Fig. 2, C and D) or lung (Fig. 2, E and F), are shown. To monitor
specific changes between sham and injury, we replotted our scRNAseq
data separately for sham and injury of the kidney or lung. On the
basis of number of cells captured in each population (Seurat cluster),
the injured kidney in comparison to sham showed easily detectable
and expected dynamics in the immune cell compartment, with
strong enrichment of neutrophils and monocytes in the injured
sample (Fig. 2G). Similar but somewhat more subtle changes were
detected in the same immune cells in the remotely injured lung. We
detected a strong increase in the number of neutrophils and a small
increase in monocytes in remotely injured lung tissue (Fig. 2H).
Changes in lung IM numbers between sham and injury were less
appreciable at this level of our scRNAseq analysis, although we detected them in large numbers (Fig. 2, G and H).
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Fig. 1. Ischemic AKI causes severe ALI. (A) Experimental scheme: AKI ➔ AKI-ALI model sham, days 1, 3, and 5 after AKI. (B) Serum BUN values after sham or AKI, days 1
to 5. (C) Serum creatinine values after sham or AKI, days 1 to 5. (D) Hematoxylin and eosin (H&E) stain lung after sham or AKI, days 1 to 5. (E) Alveolar wall thickness measurements after sham or AKI, days 1 to 5. (F) Lung neutrophils (Ly6G+, green), alveolar macrophages (AMs) (CD68high, large, red), and IMs (CD68low, small, red) and quantification after sham or AKI, days 1 to 5. 4′,6-diamidino-2-phenylindole (DAPI) stain (blue) was used to visualize nuclei. (G) CyTOF: lung neutrophils (CD45+ and Ly6G+),
alveolar macrophages (CD45+, CD68high, and Siglec-F+), and lung IMs (CD45+, CD68low, and Siglec-F−), day 1. (H) BAL protein/albumin analysis: serum BUN elevations and
BAL fluid protein/albumin after sham or AKI, day 1. Total protein was detected by the Pierce BCA Protein Assay. Albumin was detected by enzyme-linked immunosorbent
assay (ELISA). (I) BAL immune cell analysis: Total immune cells, macrophages, and neutrophils were detected by fluorescence-activated cell sorting (FACS). (J) Arterial
blood oxygen partial pressure (PO2) after sham or AKI, day 1. (K) Lung hematoxylin and eosin after sham or nephrectomy (Nx), day 1. (L) Alveolar wall thickness after sham
or nephrectomy, day 1. (M) CyTOF: Lung neutrophils (CD45+ and Ly6G+), alveolar macrophages (CD45+, CD68high, and Siglec-F−), and lung IMs (CD45+, CD68low, and
Siglec-F−) were quantified after sham or nephrectomy, day 1. n = 4 to 8 animals per measurement. *P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.05, ##P < 0.01, and ###P < 0.001.
NS, not significant.
Khamissi et al., Sci. Adv. 8, eabm5900 (2022)
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Fig. 2. scRNAseq of kidney and lung in setting of AKI-ALI. (A) Experimental scheme: scRNAseq 10x Genomics of kidney and lung day 1 after sham or AKI. (B) Serum BUN
values after sham or AKI, day 1. (C) Seurat object: combined kidney sham and AKI, day 1. (D) Marker genes used for definition of kidney cell types. (E) Seurat object: combined lung sham and AKI-ALI lung, day 1. (F) Marker genes used for definition of lung cell types. (G) Seurat objects: sham kidney versus AKI kidney, day 1, quantification
of neutrophils, monocytes, and macrophages in sham or AKI samples expressed as the percentage of total cells detected by Seurat. (H) Seurat objects: sham lung versus
AKI-ALI lung, day 1, quantification of neutrophils, monocytes, and macrophages in sham or AKI samples expressed as the percentage of total cells detected by Seurat. Cell
types: epithelial: AT1/2, type 1/2 lung epithelial cell; PT, proximal tubule; TAL, thick ascending limb; DTL, descending-type thin limb; ATL, ascending-type thin limb. Endothelial: EC, endothelial cell (a, arterial; v, venous; c, capillary). Stromal: FIB, fibroblast; PERI, pericyte. Immune cells: NT, neutrophil; DC, dendritic cell; M, macrophage; AM;
IM; Mono, monocyte; MegaK, megakaryocyte; Plasma B, plasma B cell; B cell; T cell. n = 4 animals per measurement. ***P < 0.001.
Khamissi et al., Sci. Adv. 8, eabm5900 (2022)
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Fig. 3. L-R pairing analysis across organs, linking ligands expressed in the kidney to receptors expressed in the lung. (A) Experimental scheme: design of L-R pairing analysis, kidney ligands paired to lung receptors using kidney and lung scRNAseq data and CellPhoneDB analysis. (B) L-R pairing analysis kidney nonimmune cells to
lung nonimmune cells for day 1 after sham (panel 1) or AKI (panel 2). P values shown are empirical P values calculated by CellPhoneDB, and higher values indicate higher
L-R pairing significance.

Whether T cell released CCL5 or CCL5, in general, is involved in
AKI-ALI is unknown.
We validated our CellPhoneDB analysis using two approaches.
First, we used a previously published snRNAseq dataset that assessed kidney gene expression at early time points after AKI for our
Khamissi et al., Sci. Adv. 8, eabm5900 (2022)
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L-R pairing analysis (19). We linked their kidney snRNAseq dataset
of 4 and 12 hours after AKI to our scRNAseq data of the remotely
injured AKI-ALI lung at day 1 after AKI. L-R pairing analysis identified OPN:CD44 as a top hit. Kidney distal tubule OPN pairing
with CD44 receptor in lung immune and nonimmune cell types
5 of 19
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OPN is up-regulated in kidneys but not in lungs
during AKI-ALI
To understand the relationship between OPN and the development
of AKI-ALI, we assessed expression patterns of OPN mRNA and
OPN protein serum levels during the course of AKI. On the basis of
our scRNAseq data, OPN mRNA is already expressed at significant
levels in distal tubule and to a lesser degree in proximal tubule cells
of sham kidneys (Fig. 4A, top). On day 1 after AKI, OPN expression
was not only most significantly increased in both proximal and distal tubule cells but, now, also present at lower levels in other cell
types such as endothelial cells, fibroblasts, neutrophils, macrophages,
and T cells (Fig. 4A, bottom). This suggests that tubule-released
OPN could potentially act in the induction phase of AKI-ALI and
that, at later stages, various cellular OPN sources, including immune
cells, might contribute to elevated OPN serum levels. We validated
these findings by comparing our scRNAseq data with previously published snRNAseq AKI data (19). Similar to our dataset, OPN mRNA
expression in sham kidneys was present in both proximal tubule cells
(PTC and new PTC) and distal tubule cells [CNT (connecting tubule),
descending-type thin limb–ascending-type thin limb (DTL-ATL),
DCT (Distal Convoluted Tubule), and Uro (Urothelium)]. By 4 hours
after AKI, OPN mRNA expression began to increase significantly in
several cell types, and by 12 hours, OPN mRNA expression was very
high in proximal and distal tubules, endothelial cells, fibroblasts,
neutrophils, macrophages, and T cells, similar to our dataset on day 1
after AKI. OPN expression remained elevated for several weeks in
distal tubular compartments (Fig. 4B). In contrast to the kidney,
OPN expression in sham lung was only present in moderate levels in
pericytes and, to a lesser degree, in resident alveolar macrophages.
AKI injury did not change the overall low OPN expression levels
detected by scRNAseq in the lung on day 1 after AKI (Fig. 4C, top
and bottom), suggesting that the kidney but not the lung represents a
substantial source of OPN after AKI. To better understand dynamic
changes in our model, we performed additional AKI-ALI experiments, evaluating earlier time points. We subjected C57BL/6 mice
to AKI and euthanized them 1, 2, 4, 6, and 12 hours later (Fig. 4D,
experimental scheme). In Figs. 4 and 5, we are also incorporating
Khamissi et al., Sci. Adv. 8, eabm5900 (2022)

25 February 2022

AKI-ALI data from day 1, 3, or 5 after AKI derived from Fig. 1 for ease
of viewing. Serum BUN and serum creatinine levels were already significantly elevated 1 hour after AKI (Fig. 4, E and F), and serum kidney injury molecule-1 (KIM-1; a sensitive marker of kidney injury)
was elevated at 12 hours (Fig. 4G), indicating substantial kidney injury.
Kidney OPN expression was already significantly elevated 2 to 4 hours
after AKI, reached a peak by 12 hours, and remained elevated until at
least day 5. Lung OPN expression, however, remained virtually undetectable or very low over the same time (Fig. 4H). Serum OPN protein
levels closely followed changes in kidney OPN mRNA expression
(Fig. 4I). The early rise in OPN serum levels is likely enabled by the
existing baseline expression of OPN in the sham kidney (Fig. 4,
A and B). Elevated OPN levels in AKI-injured mice correlated with
the degree of kidney injury (BUN/OPN) (Fig. 4J).
Serum OPN protein levels have been studied as a biomarker of
severity of disease in patients with multiorgan failure, often including
AKI and ALI (31, 32). Whether serum OPN levels are also elevated
in patients with AKI before development of multiorgan failure is not
known. We examined OPN serum levels in patients with AKI that
did not have multiorgan failure and were not critically ill. Serum OPN
levels were significantly elevated in patients with AKI, as compared
to healthy controls or patients with chronic kidney disease (CKD)
(Fig. 4K) and positively correlated with reduced kidney function as
determined by serum creatinine measurements (Fig. 4L). These findings suggest that AKI in humans could result in release of substantial
amounts of OPN into the circulation and raise the possibility that circulating OPN may promote damage at remote sites also in humans.
We hypothesized that for OPN to act on lung and cause AKIALI, it might need to gain access to the lung tissue compartment
from the circulation. Alternatively, it could act on cells directly accessible from the circulation, such as endothelial cells or circulating
immune cells. We thus examined whether OPN can gain access to
lung tissue from the circulation in the setting of AKI in mice. We
injected fluorescently labeled OPN after sham operation or after
AKI at the time of reperfusion and euthanized animals 30 min or
1 hour after injection. We costained for nidogen, a marker of the extracellular matrix/interstitial space. Sham-operated animals did not
accumulate any significant amount of fluorescently marked OPN in
the lung within 1 hour of injection, whereas animals with AKI showed
OPN accumulation in lung interstitium (thin arrows) and colocalization with lung cells (thick arrows) at 30 min or 1 hour after injection (fig. S4). Ly6G, CD68, and CD44 costains reveal that injected
fluorescently marked OPN colocalizes with CD68+ alveolar macrophages and IMs (which also show the highest staining for CD44) but
not with Ly6G-positive neutrophils (Fig. 4M). Together, our results
indicate that kidney rather than lung represents the source of circulating OPN protein after AKI and that circulating OPN can principally
gain access to the lung early after AKI and thus might mediate the
induction of remote lung injury. As predicted from the L-R pairing
analysis in Fig. 3, CD44 in lung immune cells, particularly alveolar
macrophages and IMs, may represent important targets of OPN released from the kidney. Access to the lung was marginal in sham-
operated animals, leading us to the conclusion that another AKI-released
factor must cooperate with OPN to allow OPN access to lung tissue.
AKI triggers lung endothelial barrier dysfunction
and immune cell accumulation very early after injury
Consistent with the timing of elevated OPN serum levels after AKI,
lungs already showed significant signs of injury with interstitial
6 of 19
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showed high significance at 4 hours after AKI. At 12 hours after
AKI, OPN derived from several kidney cell types including distal
tubule cells, endothelial cells, fibroblasts, macrophages, and T cells
pairing with CD44 in lung immune or nonimmune cells represented
the top scoring L-R pairing (fig. S2, A and B). Second, we used a list
of all secreted proteins identified in UniProt and added a hand-
curated list of additional secreted or metalloprotease released proteins of interest and assessed their average expression in all cell types
of our AKI kidney scRNAseq dataset. In this analysis, OPN also
emerged as the top distal tubule secreted molecule after AKI, and none
of the secreted proteins, which were not included in CellPhoneDB,
showed a comparable increase.
OPN (SPP1), initially identified as a regulator of bone biomineralization and remodeling, is an immunoregulatory molecule expressed in a variety of cells, including stromal, epithelial, and immune
cells (24–28). OPN is strongly chemotactic for immune cells, in particular, for neutrophils and macrophages and enhances T helper 1
inflammation (29, 30). Taking these immunoregulatory features of
OPN and our L-R pairing analysis and in silico validation into account, we hypothesized that OPN might be a good candidate AKI-
ALI mediator to study in our AKI-ALI model.
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Fig. 4. OPN is up-regulated in kidneys but not lungs during AKI-ALI. (A) Kidney scRNAseq: OPN expression after sham (top) or AKI (bottom). (B) Kidney snRNAseq (20):
OPN expression after sham or 4 hours, 12 hours, 2 days, 14 days, and 6 weeks after AKI. (C) Lung scRNAseq: OPN expression after sham (top) or AKI (bottom). (D) Experimental scheme: AKI ➔ AKI-ALI model. Sham, 1, 2, 4, and 12 hours after AKI. We integrated measurements from days 1, 3, and 5 after AKI (Fig. 1) in some panels of Fig. 4.
(E) Serum BUN after sham or 1 to 12 hours and days 1, 3, and 5 after AKI. (F) Serum creatinine after sham or 1 to 12 hours and days 1, 3, and 5 after AKI. (G) Serum KIM-1
after sham or 1 to 12 hours and days 1, 3, and 5 after AKI. (H) Kidney + lung quantitative polymerase chain reaction (qPCR): OPN expression after sham or 1 to 12 hours
and days 1, 3, and 5 after AKI. (I) Serum ELISA: OPN protein after sham or 1 to 12 hours and days 1, 3, and 5 after AKI. (J) Serum BUN/OPN correlation using BUN and OPN
measurements across all time points. (K) Serum ELISA: human OPN protein levels in patients with AKI compared to healthy controls and patients with chronic kidney
disease (CKD). (L) Correlation of OPN serum levels with serum creatinine concentration in patients with AKI. (M) Colocalization of OPN Alexa Fluor 555 (Alexa 555) with
CD68+/CD44+ alveolar macrophages (fat arrows) and IMs (thin arrows) but not with Ly6G+ neutrophils. Arrows show colocalization with CD68/CD44. n = 3 to 8 animals
per measurement. *P < 0.05, **P < 0.01, and ***P < 0.001. ND, not detected; i.v., intravenous.
Khamissi et al., Sci. Adv. 8, eabm5900 (2022)
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Fig. 5. AKI triggers lung endothelial barrier dysfunction and immune cell accumulation very early after AKI. (A) Lung hematoxylin and eosin stain after sham or
1 to 12 hours after AKI. (B) Alveolar wall thickness measurements after sham or 1 to 12 hours and days 1, 3, and 5 after AKI. (C) Lung neutrophils (Ly6G+, green), alveolar
macrophages (CD68high, large, red), and IMs (CD68low, small, red) and quantification after Sham or AKI days 1, 3, and 5 after AKI. DAPI stain (blue) was used to visualize
nuclei. (D) Lung Evans blue leakage after sham or 1 to 4 hours after AKI. (E) Lung Evans blue quantification [optical density at 620 nm (OD620) per gram of lung dry weight]
after sham or 1 to 4 hours after AKI. (F) Lung electron microscopy and quantification of endothelial tight junction length (in nanometers) at day 1 in sham or day 1 after
AKI in wt control or OPN–global KO mice. (G) Lung scRNAseq: expression of endothelial barrier proteins in lung endothelial cells day 1 after sham or AKI; Tjp1: zonula
occludens-1 (ZO-1) and claudin-5 (Cdnl5). (H) Lung ZO-1 protein expression [immunofluorescence (IF)]: ZO-1 (red), CD31 (green, marking endothelial cells), DAPI (blue,
marking nucleus), and quantification day 1 after sham or AKI. (I) Lung qPCR: ZO-1 expression day 1 after sham or AKI. n = 3 to 6animals per measurement. *P < 0.05,
**P < 0.01, and ***P < 0.001.
Khamissi et al., Sci. Adv. 8, eabm5900 (2022)
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Pharmacological or genetic inhibition of OPN protects
from ALI after AKI
To assess whether OPN is necessary for the development of AKIALI, we subjected C57BL/6 mice to bilateral IRI and injected the
animals with either control immunoglobulin G (IgG) or anti-OPN
neutralizing antibody. Analogous experiments were performed in
OPN–global KO or wt mice without antibody treatments (Fig. 6A,
experimental scheme). Anti-OPN antibody–treated mice or OPN–
global KO mice experienced the same degree of kidney injury on
day 1 as controls, as evidenced by comparable elevations in serum
BUN and KIM-1 levels (Fig. 6, B and C). However, lung injury was
significantly ameliorated after treatment with anti-OPN antibody
and in OPN–global KO mice (Fig. 6, D and E). While anti-OPN
antibody strongly reduced lung neutrophil and IM accumulation
after AKI, OPN–global KO prevented it almost completely (Fig. 6F).
Anti-OPN antibody–treated animals also showed strongly reduced
Khamissi et al., Sci. Adv. 8, eabm5900 (2022)

25 February 2022

vascular leakage and improved lung function as compared to controls on day 1 after AKI (Fig. 6, G to I). Together, our results identify
circulating OPN as a critical and necessary regulator of lung endothelial barrier permeability, lung immune cell accumulation, and
functional impairment in AKI-ALI.
Circulating OPN is sufficient to induce ALI after AKI
To determine whether OPN suffices to mediate AKI-ALI, we tested
the effect of OPN injection in the context of mild AKI (reduced
ischemia time), an experimental condition where AKI-ALI is not
detectable at 6 hours after AKI (Fig. 7A, experimental scheme). As
expected, serum OPN levels were significantly lower in mild AKI
than severe AKI (Fig. 7B). Serum BUN levels were significantly elevated at 6 hours after mild AKI compared to sham controls but lower
compared to severe AKI (Fig. 7C). Intravenous injection of OPN
protein into mild AKI animals at the time of kidney reperfusion at
quantities that would mimic serum concentrations at 6 hours after
severe AKI (see Fig. 4I) triggered AKI-ALI that was now comparable to severe AKI-ALI (Fig. 7, E and F). We also performed OPN
injections into uninjured mice but were unable to detect increases in
alveolar wall thickness or inflammatory changes in the lung (fig. S3),
suggesting that a second event or mediator induced by AKI is required
for OPN to successfully induce AKI-ALI. Therefore, we conclude
that OPN is sufficient to induce AKI-ALI only in the context of AKI.
Circulating OPN relevant for induction of AKI-ALI is released
from the injured kidney
Up-regulated OPN expression and serum levels have been found in
the context of a number of organ injuries (31, 32, 39–45), allowing
for the possibility that OPN sources in the body other than the kidney might be relevant in AKI-ALI. Conversely, it has never been
conclusively shown that a proposed AKI-ALI mediator is released
directly from the injured kidney. To address this question, we performed kidney transplantation experiments, where we transplanted
either ischemic wt kidneys or ischemic OPN–global KO kidneys into
syngeneic C57BL/6 mice (Fig. 8A, experimental scheme). KIM-1
kidney mRNA expression and tubular injury scores document that
transplanted OPN–global KO kidneys show kidney injury parameters comparable to those in transplanted wt kidneys (Fig. 8, B and C).
Serum BUN and creatinine measurements would be unaffected in
our transplantation model, given that two intact kidneys are present
in the mouse as well. OPN serum levels were elevated above sham
levels in mice that received wt kidneys but not in mice that were
transplanted OPN-KO renal grafts. Notably, OPN serum levels are
lower with only one injured transplant kidney, as compared to the
bilateral IRI model, where two kidneys are injured (Fig. 8D; see also
Fig. 4). Lung injury developed in mice that received wt kidneys but
not in those that received OPN-KO kidney grafts (Fig. 8, E to I).
These results conclusively identify the kidneys as the source of OPN
during the development of ALI after AKI. Last, when ischemic wt
kidneys are transplanted into OPN–global KO mice (Fig. 9A), the
protection of the latter from developing AKI-ALI is reversed, and these
mice develop AKI-ALI similar to wt mice transplanted with ischemic
wt kidneys (Fig. 9B). Alveolar wall thickness increases (Fig. 9C), and
infiltration of immune cells is now equal to the effect of wt kidney
transplant into wt mice (Fig. 9D). OPN released from the transplanted wt kidney is detectable in the lung and colocalizes with
CD68+ and CD44+ alveolar macrophages and IMs but not with
Ly6G+ neutrophils (Fig. 9E), identical to exogenously injected OPN
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expansion and increased cellularity by 1 hour after AKI, which
worsened progressively over the subsequent 12 hours (Fig. 5A, also
compare to Fig. 1D). Alveolar wall thickness increased significantly
by 1 hour (>1.3-fold increase over sham), worsened progressively over
the ensuing 12 hours (>1.5-fold increase over sham), and reached a
peak at day 1 after AKI (>1.85-fold increase over sham) (Fig. 5B).
Consistent with these findings, accumulation of neutrophils and
macrophages showed a similar trend to the timeline of changes in
kidney OPN mRNA expression and serum OPN levels (Fig. 5C).
Endothelial homeostasis is disrupted in ALI or its most severe
form, ARDS, which often occurs in response to direct lung injury,
such as by coronavirus disease 2019 (COVID-19) lung infection
(33), or as a secondary organ complication of sepsis (34, 35). Severe
ALI/ARDS is characterized by diffuse endothelial injury, intense
activation of the coagulation system, and increased capillary permeability (33, 36). Increased vascular barrier permeability has also
been reported in animal models of AKI (13, 37, 38). We thus set out
to examine whether endothelial barrier disruption, a hallmark of
lung injury, also occurs following AKI in our model. Vascular leakage, as evidenced by Evans blue dye uptake, was already detectable
at a level twice as high as sham controls at 1 hour after AKI, which
was maintained for at least 4 hours (Fig. 5, D and E). Electron microscopy also showed that, compared to sham controls, endothelial
tight junctions in AKI-injured C57BL/6 animals were shortened in
length or disrupted in day 1 AKI-ALI lungs. By contrast, AKI-
injured OPN–global KO mice displayed normal endothelial tight
junctions, comparable to sham-operated wt animals (Fig. 5F). We
next assessed lung endothelial cells. Using our scRNAseq data, we
found that the expression levels of two endothelial barrier proteins,
zonula occludens-1 [ZO-1; Tjp1 (tight junction protein 1)] and
claudin-5 (Cldn5), were strongly down-regulated in AKI-ALI samples
as compared to sham lungs (Fig. 5G). We validated our finding on the
protein level for ZO-1. ZO-1 staining was heavily present in the
capillary network of sham lung but severely diminished in the capillary network of the AKI-ALI lung. CD31 (green) was used as a
costain to identify endothelial cells (Fig. 5H). Other cell types in the
lung, particularly stromal cells, such as fibroblasts and lung epithelial cells (AT1/2), also expressed ZO-1 or Cldn5 at low levels, and
these expression levels did not significantly change in the AKI-ALI
lung. These results suggest that endothelial barrier dysfunction and
vascular leakage represent early events in the induction of AKI-ALI
remote lung injury in our model.
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Fig. 6. Pharmacological or genetic inhibition of OPN protects from ALI after AKI. (A) Experimental scheme: AKI ➔ AKI-ALI model day 1 after AKI. In the following, wt
mice injected with control goat IgG are compared to OPN neutralizing antibody (OPN Nab) injected mice, and OPN–global KO animals (OPN KO) are compared to wt
controls. i.p., intraperitoneal. (B) Serum BUN values after sham or AKI, day 1. (C) Serum KIM-1 values after sham or AKI, day 1. (D) Lung hematoxylin and eosin stain after
sham or AKI, day 1. (E) Alveolar wall thickness measurements after sham or AKI, day 1. (F) Lung neutrophils (Ly6G+, green), alveolar macrophages (CD68high, large, red),
and IMs (CD68low, small, red) and quantification after sham or AKI, day 1. DAPI stain (blue) was used to visualize nuclei. (G) Lung Evans blue leakage day 1 after sham or
AKI. (H) Lung Evans blue quantification (OD620 per gram of lung dry weight) day 1 after sham or AKI. (I) Arterial blood oxygen partial pressure after Sham or AKI, day 1. n = 3
to 8 animals per measurement. *P < 0.05, **P < 0.01, and ***P < 0.001.
Khamissi et al., Sci. Adv. 8, eabm5900 (2022)
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(see Fig. 4N). These results confirm the critical necessity for OPN in
the development of AKI-ALI and suggest again that OPN may act
on CD44-expressing macrophages in the lung.
DISCUSSION

Our work using kidney transplantation provides the first conclusive
evidence in vivo that a kidney-released circulating mediator is causally
involved in secondary organ failure after kidney injury. Neutralization of circulating OPN or OPN–global KO prevented AKI-ALI
and respiratory failure, and ischemic kidneys from OPN–global KO
mice transplanted into wt mice failed to raise serum OPN levels and
to induce AKI-ALI, as compared to transplantation of ischemic wt
kidneys into wt mice. In turn, transplanted wt kidneys reversed the
protection of OPN–global KO mice against AKI-ALI, revealing the
critical necessity of kidney released OPN for the development of
AKI-ALI. We show that distal tubule– and proximal tubule–released
OPN is poised to act as a key mediator of lung vascular leakage and
inflammation early in the lung’s response to kidney injury. The fast
response is due to OPN’s baseline expression and quick up-regulation,
causing lung vascular leakage and immune cell accumulation within
an hour, ultimately resulting in functional impairment with reduced
arterial oxygenation. This finding has implications beyond AKI, as
tissue injury due to various causes can raise OPN serum levels in
humans, including but not limited to direct lung injury by COVID-19,
bacterial pneumonia (46), sepsis from various causes (32, 47, 48), or
Khamissi et al., Sci. Adv. 8, eabm5900 (2022)
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cardiac injury (44, 47). OPN has also been described as a marker of
kidney injury and declining kidney function, as example (49, 50),
but not much is known about the mechanisms involved. All these
conditions are highly associated with multiorgan failure, particularly
AKI and ALI or its most severe form, ARDS. This suggests that OPN
up-regulation represents a conserved response to tissue injury in different organs and might link circulating OPN to secondary organ failure in general, as it is suggested by various studies of serum OPN as a
biomarker of multiorgan failure mortality in humans (32, 44, 47).
Clinically, AKI-ALI is likely underrecognized because of many confounders, such as coexisting hypervolemia or cardiac dysfunction,
which often serve as primary explanations for respiratory distress in
patients with AKI, with AKI-induced proinflammatory contributions
underestimated. In this regard, our study provides important insights.
However, it is very much clinically recognized that ARDS is negatively
affected by the presence of AKI (51) [reviewed in (52)]. In this context, alveolar macrophages in ARDS patients highly express OPN
(53, 54), and lung macrophages also express OPN in an experimental
mouse model of ALI/ARDS (53). In addition, increased OPN levels in
sputum or BAL have also been linked to inflammation and severity of
disease in other human lung diseases, such as cystic fibrosis (55),
chronic obstructive pulmonary disease (56), and asthma (57). Thus,
OPN released by the AKI kidney may represent an important modifier
of preexisting lung disease, particularly ALI/ARDS.
A study in mice connected OPN to lung injury after intestinal
ischemia (58). However, in contrast to our study, OPN was found
11 of 19
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Fig. 7. Circulating OPN is sufficient to induce ALI after AKI. (A) Experimental scheme: AKI ➔ AKI-ALI model evaluated 6 hours after mild AKI (reduced ischemia time).
Mice with mild AKI are injected with vehicle control or OPN protein, and severe AKI is used as a control. (B) Serum ELISA: OPN protein 6 hours after sham, severe AKI (positive control), or mild AKI. (C) Serum BUN 6 hours after sham, mild AKI ± OPN injection, or severe AKI (positive control). (D) Lung hematoxylin and eosin stain 6 hours after
sham, mild AKI ± OPN injection, or severe AKI (positive control). (E) Alveolar wall thickness measurements 6 hours after sham, mild AKI ± OPN injection, or severe AKI
(positive control). n = 3 to 4 animals per measurement. *P < 0.05, **P < 0.01, ***P < 0.001, and #P < 0.05.
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Fig. 8. Circulating OPN relevant for induction of AKI-ALI is released from the injured kidney. (A) Experimental scheme: Ischemic kidney transplantation. C57BL/6 wt
or OPN–global KO kidneys were transplanted into C57BL/6 wt mice (“WT-WT” or “OPN KO-WT”). (B) Kidney qPCR: KIM-1 expression in WT-WT and OPN KO-WT day 1 after
transplant. (C) Tubular injury score WT-WT or OPN KO-WT day 1 after transplant. (D) Serum ELISA: OPN protein in WT-WT and OPN KO-WT day 1 after transplant. (E) Lung
Evans blue leakage in lungs of WT-WT and OPN KO-WT day 1 after transplant. (F) Lung Evans blue quantification (OD620 per gram of lung dry weight) in WT-WT and OPN
KO-WT day 1 after transplant. (G) Lung hematoxylin and eosin stain of WT-WT and OPN KO-WT day 1 after transplant. (H) Alveolar wall thickness measurements of WT-WT
and OPN KO-WT day 1 after transplant. (I) Lung neutrophils (Ly6G+, green), alveolar macrophages (CD68high, large, red), and IMs (CD68low, small, red) and quantification
in WT-WT and OPN KO-WT day 1 after transplant. DAPI stain (blue) was used to visualize nuclei. n = 4 to 7 animals per measurement. *P < 0.05, **P < 0.01, and ***P < 0.001.

up-regulated at comparably low levels in both the ischemic gut and the
remotely injured lung, not allowing to identify the source of comparably low serum OPN elevations. OPN neutralization significantly
improved gut injury but only mildly improved lung injury (59), suggesting that OPN does not represent a major causal link in gut injury–
induced lung injury. A study using renal transplantation to induce
ischemic AKI in rats showed that OPN is up-regulated in the lung and
Khamissi et al., Sci. Adv. 8, eabm5900 (2022)
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at rather low levels in serum at day 1 after transplantation; kidney was
not assessed as an OPN source. OPN inhibition with hydrodynamic
siRNA injection improved lung necroptosis and inflammation (59),
but its effects on serum or lung OPN expression were not tested. Thus,
similar to the study with intestinal ischemia, this study also did not
identify OPN as a causal interorgan signal in AKI-ALI. Broadening
the putative relevance of our study is the fact that remote organ effects
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Fig. 9. Circulating OPN released from the injured kidney reverses protection of OPN-KO mice from AKI-ALI. (A) Experimental scheme: Ischemic kidney transplantation. wt kidneys were transplanted into wt or OPN–global KO mice (WT-WT or “WT-OPN KO”). (B) Lung hematoxylin and eosin stain at day 1 after transplant for WT-WT and
WT-OPN KO. Sham lung and OPN KO-WT (see also Fig. 8A) are shown for comparison. (C) Alveolar wall thickness measurements on day 1 after transplant. (D) Lung neutrophils (Ly6G+, green), alveolar macrophages (CD68high, large, red), and IMs (CD68low, small, red) and quantification in lungs of sham-operated mice, WT-WT, OPN KO-WT,
or WT-OPN KO day 1 after transplant. DAPI stain (blue) was used to visualize nuclei. (E) Colocalization of endogenous OPN released from transplant with CD68+/CD44+
alveolar macrophages (fat arrows) and IMs (thin arrows) but not with Ly6G marker (neutrophils). Arrows show colocalization with CD68/CD44. n = 4 to 7 animals per
measurement. *P < 0.05, **P < 0.01, ***P < 0.001, and ###P < 0.005.

after AKI can also be detected in a number of other organs, including the heart and brain (11). OPN serum levels are elevated in the
systemic inflammatory response syndrome and sepsis (48) and predict mortality in patients with sepsis and multiorgan failure (31, 32).
Khamissi et al., Sci. Adv. 8, eabm5900 (2022)
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One published study, which reported as primary outcome that
persistently elevated OPN serum levels correlate with increased
mortality in multiorgan failure patients, also suggested in secondary
analysis that OPN serum levels are correlated to increased need of
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on AKI-ALI (15). We also identified moderate to low significance
L-R pairing of kidney TNF with its lung receptor TNFR2 (Tnfrsf1b)
in immune cells but not stromal cells; however, the significance
of these pairings did not increase with injury (Fig. 3, B to D, and fig.
S2). Similar to TNF, IL6 was linked to AKI-ALI using IL6 neutralization and IL6 global KO mice (16). IL6 and its receptor, however,
were not identified by our analysis.
We did not find significant lung changes after bilateral nephrectomy.
Others have, however, demonstrated changes in gene expression
profiles and lung inflammation after nephrectomy (66, 67), and the
elimination of AKI-induced cytokines can be delayed by nephrectomy
(16). In our experiments, we can detect small changes in serum
OPN even after sham surgeries, without kidney injury or nephrectomy, possibly induced by the relatively small tissue injury induced
by sham surgery. It is thus possible that the detection of lung changes
after nephrectomy depends, at least, in part, on the extent of tissue
injury caused by the surgeon. This might explain some of the discrepancies between our work and the work of others.
OPN, also known as SPP1, early T lymphocyte activation-1, or
uroprotein (26, 27, 30) is a member of the small integrin-binding
ligand N-linked glycoprotein family proteins. OPN has, at least, two
types of receptors, both broadly expressed in many cell types but
highly up-regulated particularly in immune cells. It can interact
with integrins via N-terminal domains and CD44 receptors via
C-terminal domains. OPN interaction with CD44 causes chemotaxis
of neutrophils and macrophages, whereas interactions with integrins
relay immune cell spreading and activation signals (68–71). OPN
(SPP1):integrin pairings were, however, not detected in our analysis.
In the case of the two other predicted significant OPN (SPP1) L-R
pairings, SPP1:CCR8 and SPP1:PTGER4 (prostaglandin E receptor 4)
(Fig. 3B and fig. S2), it is unclear whether these interactions produce
cellular signals, as these pairings were predicted by CellPhoneDB
on the basis of protein-protein interaction data curated from various experimental approaches (22, 23), but it is not known whether
these interactions produce a cellular signal. Which target cells are
affected by OPN in our model remains to be determined. In our lung
scRNAseq dataset, CD44 is broadly expressed at low levels in lung
stroma but robustly expressed in immune cells and highly up-regulated
by injury in lung neutrophils, monocytes/macrophages, and T cells.
This suggests that OPN might preferentially target immune cells
rather than stromal cells of the lung.
In summary, our work identifies circulating OPN released by the
injured kidney as a causal key mediator of lung endothelial leakage,
lung edema, and lung inflammation with respiratory compromise.
Our human sample data and available published evidence suggest
that therapeutic targeting of OPN or of its associated regulatory or
target components should be evaluated in patients with multiorgan
failure that are at high risk of ALI or that already have ALI, particularly in the presence of AKI. Any benefit in this area could lead to a
meaningful if not substantial reduction of the very high mortality of
multiorgan failure.
MATERIALS AND METHODS

Animals
For all studies, adult (8 to 12 weeks old) male mice were used in
accordance with the animal care and use protocol approved by the
Institutional Animal Care and Use Committee of Washington University School of Medicine. C57BL/6J (B6) (JAX stock no. 000664)
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ventilation (47), but proof of this would require new clinical trials
designed to detect effects of serum OPN neutralization on respiratory outcomes. A study of critically ill patients with multiorgan
failure including AKI requiring dialysis found that OPN levels in
this cohort were significantly elevated when compared with critically
ill controls without AKI (44), possibly indicating that the degree of
kidney injury correlates with the degree of serum OPN elevation.
Our results show that serum OPN is elevated in cases of human AKI
(no multiorgan failure or sepsis) and correlates with the degree of
kidney injury, strengthening the link between elevated OPN serum levels
and kidney injury in humans. Together, published data and our
results suggest that circulating OPN might have similar roles in
AKI-ALI with respiratory failure in humans as we detect in mice.
Our studies also identify circulating OPN as a key regulator of
endothelial barrier permeability in vivo in AKI-ALI. Disruption of
the lung endothelial barrier and/or the pulmonary epithelial barrier
is a common feature of ALI/ARDS (34). A number of other studies
have also reported lung vascular leakage after AKI [e.g., (18, 37, 60)]
and lung endothelial cell activation (61). For the AKI-ALI mediator
TNF, this may be related to TNFR1-dependent lung endothelial cell
apoptosis (15). However, while IL6 and TNF inhibition have been
reported to strongly reduce lung neutrophil accumulation after
AKI, they only moderately reduce lung vascular leakage (15, 37).
How IL6 and TNF relate to OPN’s ability to disrupt the endothelial
barrier is unknown. A previous study associated OPN with endothelial
barrier permeability in pulmonary vein endothelial cells (PUVECs)
in primary culture. In this report, OPN expression was increased,
and ZO-1 and Cldn5 expression levels were decreased in PUVECs
in septic rats or in lipopolysaccharide-treated PUVECs isolated from
these rats. Up-regulation of connexin43 in PUVECs stimulated
OPN expression and down-regulated ZO-1 and Cldn5, increasing
vascular permeability. OPN knockdown blocked this effect (62, 63).
These data are consistent with our findings of ZO-1 and Cldn5
down-regulation in single-cell expression data of lung endothelial
cells (Fig. 5G) and down-regulation of ZO-1 protein in immuno
fluorescence stains of AKI-ALI lung tissue (Fig. 5H). In addition,
principally consistent with our findings, OPN was found up-regulated
by the host and tumor in a mouse model of malignant pleural effusions where OPN neutralization reduced leakage of fluid into the
pleural space (64, 65).
TNF and its family member lymphotoxin A were also found in
our L-R pairing analysis, adding additional validity to our strategy
and findings. Circulating TNF is thought to participate in the induction of lung endothelial cell death via its receptor TNFR1, as
neutralization of TNF with etanercept in AKI-injured wt mice or
use of global TNFR1 KO mice reduced lung cell apoptosis after AKI
(15). We identified various moderate to low significance pairings of
TNF with its cognate receptors, particularly TNF:TNFR1, and other
known interacting proteins (fig. S2). These TNF pairings were primarily identified between kidney immune cells and lung stromal or
immune cells when pairing sham kidney with sham lung or at somewhat higher significance when pairing early AKI kidney (4 and
12 hours) with day 1 AKI-ALI lung. However, most of these pairings
lost significance when day 1 AKI kidney was paired with day 1 AKIALI lung (Fig. 3, D and E, panels 1 and 2, and fig. S2). This suggests
that TNF plays a role early in the development of AKI-ALI, consistent
with the role of TNF as a type 1 inflammatory cytokine known to act
early in establishing inflammation, and this is also consistent with the
referenced study of the effect of TNF inhibition/TNFR1 deficiency
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and B6.129S6(Cg)-Spp1tm1Blh/J (OPN−/−) (JAX stock no. 004936)
were purchased from the Jackson Laboratory.

Single-cell preparation for RNA sequencing
Kidneys were minced into small pieces (<1 mm3) and incubated in
tissue dissociation buffer [Liberase TM (1 mg/ml), hyaluronidase
(0.7 mg/ml), and deoxyribonuclease (80 U/ml) in phosphate-buffered
saline (PBS)] for 30 min in 37°C. Single cells were released from the
digested tissue by pipetting 10 times, and the cell suspension was
filtered through a 70-m sieve (Falcon). Fetal bovine serum (10%)
was added to stop the enzymatic reaction. Cells were collected by
centrifugation (300g at 4°C for 5 min) and resuspended in red blood
cell (RBC) lysis buffer [155 mM NH4Cl, 10 mM KHCO3, and 1 mM
EDTA (pH 7.3)] for 1 min at room temperature. After washing in
PBS, cells were used fresh for analysis by scRNAseq.
Single-cell RNA sequencing
scRNAseq analysis of four pooled sham or four pooled AKI samples, for both kidney and lung (sham kidney/AKI kidney and sham
lung/AKI-ALI lung), was performed as described previously (74).
Briefly, cells were stained with propidium iodide, and live cells were
sorted using FACSAria III (BD Biosciences). Libraries were prepared
using the Chromium Single Cell 5’ Library Kit v2 and Chromium
instrument (10x Genomics, Pleasanton, CA). Full-length cDNA
was amplified, and libraries were submitted to Genome Technology
Access Center of Washington University in St. Louis for sequencing
at a depth of 50,000 reads. All processing steps were performed
using Seurat v3. Quality control was first performed on each library to
find appropriate filtering thresholds for each. Expression matrices
for each sample were loaded into R as Seurat objects, retaining only
cells that have more than 200 and less than 3200 genes. Poor quality
cells with >10% mitochondrial genes were removed. Any gene not
expressed in at least three cells was removed. sctransform was
used for normalization scaling and variance stabilization (https://
github.com/ChristophH/sctransform). This was done to reduce
bias introduced by technical variation, sequencing depth, and capture efficiency. We assigned an identifier for sham kidney, AKI kidney, sham lung, and AKI-ALI lung to tell them apart. Integration of
kidney and lung single-cell data was done using the harmony package (https://github.com/immunogenomics/harmony) to control for
Khamissi et al., Sci. Adv. 8, eabm5900 (2022)
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L-R pairing analysis
To infer cell-to-cell communication between kidney and lung cell
types from scRNAseq or snRNAseq data, we performed L-R pairing
analysis using CellPhoneDB (cellphonedb.org) (21). First, we integrated all datasets from kidney [sham kidney and AKI kidney
(4, 12, and 24 hours)] and lung (sham lung and AKI-ALI lung)
using reciprocal principal components analysis as implemented in
Seurat. The 4- and 12-hour AKI kidney snRNAseq data were from
published data (19). CellPhoneDB contains a highly curated set of
human protein-protein interactions and protein complexes; thus,
mouse genes were mapped to their high-confidence human one-toone ortholog using homology mappings from Ensembl. CellPhoneDB
statistical analysis was performed with default settings between all
kidney and lung cell populations, conditions, and time points simultaneously to increase statistical power. Last, we considered only coexpressed pairs with a ligand expressed in a kidney cell population
and its cognate receptor expressed in a lung cell population with
significant cell type–specific coexpression as compared to randomly
shuffled cells (P < 0.01). CellPhoneDB calculates an empirical P value
of significance, with higher P values indicating higher significance.
Histology, immunofluorescence staining, and quantification
Mice were anesthetized by ketamine cocktail [ketamine (20 mg/ml)
and xylazine (2 mg/ml) in 0.9% sodium chloride solution] and then
perfused with PBS. Lungs were harvested at the indicated times.
Four lobes of the right lung were cut and divided. For histology, two
lobes (superior and middle lobes) were inserted into 4% para
formaldehyde, located inside a 10-ml syringe, and inflated by creating
pressure with the syringe plunger after locking the syringe. After
inflation, the lobes were fixed in 4% paraformaldehyde overnight at
4°C and then processed and embedded in paraffin. Sections (4 m
in thickness) were stained with hematoxylin and eosin. Alveolar
wall thickness was measured as previously described using ImageJ
(75). For immunofluorescence, one lobe (inferior lobe) of the right
lung was placed into PBS, located inside a 10-ml syringe, inflated by
creating pressure with the syringe plunger after locking the syringe.
Fresh frozen lung sections (7 m) were fixed in 4% paraformaldehyde,
permeabilized in 0.1% Triton X-100 for 3 min, and blocked for
1 hour with 10% normal goat serum supplemented with 1% bovine
serum albumin (BSA) in PBS. Sections were incubated with primary
antibodies in blocking solution overnight at 4°C. The primary antibodies used were rat anti-mouse Ly6G/Ly6C (clone RB6-8C5,
14-5931, eBioscience; 1:100), rabbit anti-CD68 (ab125212, Abcam;
1:200), rat anti-mouse CD31 (550274, BD Pharmingen; 1:200), rabbit anti-ZO1 (ab221547, Abcam; 1:500), rat anti-nidogen (sc-33706,
Santa Cruz Biotechnology; 1:200), rat anti-mouse CD44 (550538,
BD Pharmingen; 1:200), and goat anti-mouse OPN (AF808, R&D
Systems; 1:100). After extensive washes with PBS, fluorescently
conjugated secondary antibodies were applied at 1:300 dilution for
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Surgeries
Bilateral renal ischemia for 16 or 20 min (mild AKI) at 37°C was
induced in both kidneys using the flank approach as previously reported by cross-clamping both renal pedicles (72). Sham operations
were performed with exposure of both kidneys but without induction of ischemia. Syngeneic wild-type (WT) (B6 to B6) or syngeneic
KO (OPN−/− to B6) kidney transplants were performed as follows:
Anesthesia was induced by a mixture of ketamine (80 to 100 mg/kg)
and xylazine HCl (8 to 12 mg/kg) intraperitoneally and maintained
with 1 to 2% isoflurane gas, as required. Briefly, B6 or OPN−/− donor
kidneys were implanted into the abdominal cavity of B6 recipient
mice, where the donor suprarenal aorta and renal vein were anastomosed to the recipient infrarenal aorta and inferior vena cava, respectively. The ureter was reconstructed by direct ureter to bladder
insertion (73). Donor kidneys were subjected to 20-min warm ischemia
after procurement before they were maintained on ice for implantation,
and cold ischemic times were less than 40 min. Sham-operated mice
underwent the same surgical procedure except for the transplant.

batch effects when integrating data from different samples. After
quality control and integration, 13,882 kidney cells and 15,167 lung
cells were further analyzed. We identified 15 clusters in the kidney
and 20 clusters in the lung. We visualized cell clustering using uniform manifold approximation and projection (UMAP). To assign
cluster identities, we first compiled a list of lung and kidney cell
types and their currently established markers (19, 20) and assessed
the expression of those markers and additional known canonical
markers using the FindAllMarkers() function in Seurat.

SCIENCE ADVANCES | RESEARCH ARTICLE
1 hour at room temperature. The secondary antibodies used were as
follows: Alexa Fluor 594 goat anti-rabbit (A-11037), Alexa Fluor
488 goat anti-rat (A-11006), Alexa Fluor 594 donkey anti-goat
(A-11058), Alexa Fluor 647 donkey anti-rabbit (711-605-152), and
Alexa Fluor 488 donkey anti-rat (712-545-153). For quantitative
analysis, we selected six representative areas that were captured
with a Nikon Eclipse E800 microscope at a ×200 magnification.
Electron microscopy
For transmission electron microscopy, small pieces (1- to 2-mm
cubes) of lung tissue were fixed with 2% paraformaldehyde and 2%
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4). Embedding and sectioning were performed by the Washington University
Center for Cellular Imaging. To assess the integrity of endothelial
cell-cell junction, junction length was measured from digital images
using ImageJ software expressed as a relation of electron dense
cortical protein complex area to the total length of cell-cell contact
between endothelial cells as previously described (76).

OPN-conjugation, injection, and detection
Recombinant mouse OPN (441-OP, R&D Systems) was conjugated
to Alexa Fluor 555 (A30007, Molecular Probes) according to the
manufacturer. Briefly, OPN protein was reconstituted at 1 mg/ml in
sterile PBS. One vial of Alexa Fluor 555 succinimidyl ester was dissolved in 10 l of distilled H2O. The reaction mixture containing
25 l of recombinant OPN, 1.66 l of Alexa Fluor 555, and 2.5 l of 1 M
sodium bicarbonate was incubated for 15 min at room temperature.
After purification, the concentration of the protein was read at 280
and 555 nm using NanoDrop ND-2000C spectrophotometer (Thermo
Fisher Scientific). Alexa Fluor 555–conjugated OPN was intravenously injected into mice after 20 min of bilateral renal ischemia at
reperfusion or in sham mice at an equivalent matching time point.
Mice were euthanized 30 min or 1 hour later, and mice were anesthetized and perfused via the left ventricle with 40 ml of PBS, before
lungs were removed and additionally rinsed with PBS. Lungs were

Human samples
Deidentified human samples of patients with AKI without multiorgan
failure, of patients with CKD or of healthy controls were provided
by the Kidney Translational Research Core at Washington University in St. Louis. Cause of AKI was as follows: eight acute tubular
necrosis (ATN), one oxalate crystal ATN, one AKI of obstructive
etiology, one contrast nephropathy, one ureterovesical junction
stone AKI, one AKI with HIV, and one AKI with malignant hypertension. Patients did not have clinical evidence of other organ failure based on clinical data review and serum biochemistries.
Quantitative reverse transcription polymerase
chain reaction
Total RNA was isolated from mouse kidneys and lungs using the
Direct-zol RNA MiniPrep Plus Kit (catalog no. R2072) following
the manufacturers’ instructions. Total RNA was reverse transcribed
using the QuantiTect RT Kit (QIAGEN) and real-time polymerase
chain reaction (PCR) was performed with Fast SYBR Green (QIAGEN).
Primer sequences are provided in Table 1. Glyceraldehyde-3-phosphate
dehydrogenase (Gapdh) was used as the housekeeping gene. Data
were analyzed using the Ct method.
Enzyme-linked immunosorbent assay
Human OPN, mouse OPN, and mouse KIM-1 were measured in
human or mouse serum samples using enzyme-linked immunosorbent
assay (ELISA) kits (DY1433, DY441, and DY1817, respectively, all
from R&D Systems) as per the manufacturer’s instructions. Serum
dilutions for ELISAs were as follows: mouse KIM-1 (1:10 dilution);
mouse OPN: sham (1:2000 dilution), injured (1:4000 dilution),
sham transplant (1:1000 dilution), and WT kidney transplant and
OPN-KO kidney transplant (1:2000 dilution); human serum OPN:
healthy control (1:500 dilution), patients with AKI (1:1000 dilution),
and patients with CKD (1:500).
Mass cytometry CyTOF
Single-cell preparations were analyzed by mass cytometry as previously described (78). Briefly, cells were labeled using a previously
validated and titrated antibody cocktail for surface markers (all
antibodies conjugated by the manufacturer; Fluidigm) diluted in
Fluidigm MaxPar Cell Staining Buffer (CSB) (1 hour at 4°C). After
two washes in CSB, cells were fixed in 2% paraformaldehyde for 20 min
at room temperature, washed, stained with MaxPar Intercalator-IR
(Fluidigm), and filtered into cell strainer cap tubes. Data were then
acquired on a CyTOF2/Helios instrument (Fluidigm) and analyzed
with the CytoBank software using our recently described gating
strategy (78).

Table 1. Primers.
Target gene

Primer sequence forward (5′ ➔ 3′)

Primer sequence reverse (5′ ➔ 3′)

Gapdh

ACCACAGTCCATGCCATCAC

TCCACCACCCTGTTGCTGTA

Havcr1 (Kim-1)

AAACCAGAGATTCCCACACG

GTCGTGGGTCTTCCTGTAGC

Spp1

GGATGAATCTGACGAATCTC

GCATCAGGATACTGTTCATC
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Evans blue injection
Mice were injected retro-orbitally with Evans blue dye (30 g/l;
Sigma-Aldrich) in PBS (50 g/g of body weight). After 20 min, mice
were anesthetized and perfused via the left ventricle with 40 ml of
PBS, and lungs were removed and additionally rinsed with PBS. The
left lung was cut in half, and each half was weighed. Evans blue dye
was extracted from one-half of the lung by incubation with 200 l of
formamide (56°C for 24 hours), and the concentration of Evans blue
was estimated by spectrophotometer (620 nm). The other half lung
was dried in an incubator set at 65°C. The dry weight was obtained
after 48 hours of incubation, and the ratio of wet-to-dry weight was
calculated. The resulting unit of Evans blue plasma extravasation was
optical density at 620 nm (OD620) per gram of dry weight (77).

then processed to frozen sections as described and assessed for
deposition of OPN into lung tissue by confocal microscopy.
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Renal function
Serum creatinine was assessed by a liquid chromatography–mass
spectrometry–based assay at the O’Brien Core Center for Acute
Kidney Injury Research (University of Alabama School of Medicine,
Birmingham, Alabama, USA). BUN levels were measured using the
DiUR100 kit (Thermo Fisher Scientific) according to the manufacturer’s instructions.
Statistical analysis
Statistical analyses were carried out using GraphPad Prism. Twotailed, unpaired t tests, one-sample t tests, one-way analysis of variance (ANOVA), and two-way ANOVA were used to determine
statistical significance in quantification. All results were expressed as
means ± SD, and P < 0.05 was considered as statistically significant.

SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.abm5900
View/request a protocol for this paper from Bio-protocol.
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